Novo Nordisk seeks EU and U.S. approval for new diabetes treatment

News Hour:

Danish Novo Nordisk said on Monday it has filed for the European Union and the U.S. approval of semaglutide to treat adults with type 2 diabetes, reports Reuters.

The company said the results of the clinical trial, which included more than 8,000 adults with type 2 diabetes, demonstrated statistically significant and sustained blood glucose control, and a statistically significant reduction of cardiovascular risk compared to placebo.

Avatar

This article has been posted by a News Hour Correspondent. For queries, please contact through [email protected]
No Comments

Join Epidemiology Congress 2019

Translate this News

Join the Facebook Group

Click here to join the Facebook group of News Hour

Popular Posts

Advertisement

News of the Month

Scroll Up
%d bloggers like this: